Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
2024 full-year revenue guidance raised by US$ 2 billion
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Sales reflect continued strong growth in oncology and vaccines
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Subscribe To Our Newsletter & Stay Updated
